Leveragen and Moonlight Bio Partner to Develop Next-Generation T Cell Therapies

  • Leveragen Inc. and Moonlight Bio have entered a strategic collaboration to develop advanced T cell therapies for hard-to-treat cancers.
  • The partnership combines Leveragen’s antibody discovery platform with Moonlight Bio’s expertise in T cell engineering.

Boston-based biotech company Leveragen Inc. has announced a strategic collaboration with Seattle-based Moonlight Bio to develop innovative T cell therapies aimed at treating some of the most challenging cancers. The partnership leverages Leveragen’s Singularity Sapiens Mouse platform, a proprietary tool for generating fully human single-domain antibodies, alongside Moonlight Bio’s advanced cell engineering technologies.

Under the agreement, Leveragen will lead the discovery of fully human single-domain antibodies targeting key therapeutic areas, while Moonlight Bio will oversee preclinical development of the resulting T cell therapies. The collaboration aims to enhance the functionality, persistence, and efficacy of T cell therapies, addressing existing limitations in treating solid tumors.

Weisheng Chen, Founder and CEO of Leveragen, stated, “Through this partnership with Moonlight Bio, we are combining our state-of-the-art antibody discovery platform with their advanced cell engineering capabilities to develop T cell therapies that have the potential to make a meaningful difference for patients.”

Jordan Jarjour, CSO of Moonlight Bio, added, “Leveragen’s Singularity Sapiens Mouse platform is a powerful tool for generating fully human single-domain antibodies with properties that could optimally translate into advanced T cell therapies. We are very excited to collaborate with Leveragen as we explore and create new solutions in this space.”

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.